Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palatability and Relative Bioavailability of Osivelotor Pediatric Formulations in Healthy Adults
NCT06507904Phase 1Recruiting
- Sponsor
- Pfizer
- Start
- Sep 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of osivelotor in sickle cell disease (SCD) (11 arms), sponsored by Pfizer. Primary endpoints: Mouth Feel Effect at 20 minutes, Bitter effect at 20 minutes and 4 more. Started Sep 2026; status: recruiting.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06507904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507904.